Drug tests aim to detect the presence of specific substances in the body. It typically appears on drug tests as MDMA or sometimes under its street names, Ecstasy or Molly. MDMA stands for 3,4-methylenedioxymethamphetamine, a synthetic drug known for its stimulant and psychedelic properties. Neurologically speaking, Ecstasy tickles all the right spots of your brain.
Harms and ris
Estimates from darknet market studies in 2015 suggested that MDMA was the third most popular drug (after cannabis and pharmaceuticals) purchased on the darknet, accounting for 25% of drug sales. MDMA has also developed a substantial niche in online darknet markets accessed via dedicated TOR browsers and paid for using cryptocurrencies like Bitcoin. The addiction risk ties back to its effects on neurotransmitters. MDMA, due to its psychoactive effects and potential for misuse, is a substance often tested for in various drug screening processes. When sold in pill form, two pills with the same logo or symbol may have different effects — they can come from different sources and have different ingredient
These detections have generally been small in quantity with the powders containing a range of different substances – always ketamine and MDMA, and typically additional substances including cocaine, caffeine or cathinones.
Adulteration of MDMA occurs by adding other psychoactive substances, typically stimulants, to MDMA in tablet, powder or crystal form. PMK glycidate, first reported in Europe in 2013, had a particular role in this resurgence (see Section Production - designer precursors substitute scheduled MDMA starting materials). In 2009 and the following years, it was therefore unlikely that consumers who purchased ecstasy in Europe would obtain unadulterated MDMA. In 2009, on average, only 31 % of the tablets analysed contained MDMA alone, compared with almost 100 % in 2004. This includes law enforcement pressure, a variety of factors affecting MDMA production, such as the availability of MDMA precursors, and, more generally, globalisation of the illicit drug supply chain
In fact, it could be argued that MDMA in the form of ecstasy tablets became cheaper between 2012 and 2019 as tablets containing larger quantities of MDMA became increasingly available on the market (see Section The trend of large tablets containing more MDMA may be reversing
This increase coincided with a period of increased purity and availability of MDMA in these markets, suggesting that changes in MDMA supply may result in serious public health risks. Furthermore, when factoring in the higher price of MDMA in Sweden, the market value in Stockholm is about 3.5 times that of Brussels. City-level market buy mdma size estimates were developed for Brussels, in Belgium, and five cities in Sweden (see Table 6.1. Estimated value of MDMA consumed in selected European cities, 2020). The price data used was the average retail price for MDMA in the country concerned, drawn from the EUDA’s annual data collection (see Section Price and purity).
Da
While a slight decrease in price was observed in 2022 for ecstasy tablets, this may not be statistically significant or sustained in the coming years. In fact, it could be argued that MDMA in the form of ecstasy tablets became cheaper between 2012 and 2019 as tablets containing larger quantities of MDMA became increasingly available on the market (see Section The trend of large tablets containing more MDMA may be reversing). For countries reporting data in 2022, a considerable retail price range was observed, with prices per ecstasy tablet ranging from EUR 4 to EUR 19 (mean) and prices of MDMA powder from EUR 6 to EUR 50 per gram. Occasionally, tablets containing 250 milligrams or more of MDMA are encountered on EU drug markets. This trend may be a combination of the scheduling of PMK glycidate, and a reduction in demand for MDMA during the COVID-19 pandemic, and is in line with the changes observed in the adulteration of ecstasy tablets (see Section Ecstasy adulteration is responsive to market pressures). This means that the ratio of MDMA to fillers (excipients) in the mixtures used to make ecstasy tablets did not increase over this time period.
Alcohol was co-consumed across 67 % of all MDMA-related hospital emergencies, and the other drugs commonly consumed alongside MDMA included cocaine, amphetamine, methamphetamine, ketamine, heroin, GHB and cannabis. The median percentage of drug-related presentations involving MDMA was 4.7 % across the reporting hospitals in 2022, and 2.8 % for presentations involving MDMA as the sole drug reported. For example, in Germany, MDMA was mentioned in 1 in 25 fatal overdoses in 2022, with most of the cases involving multiple drugs. This increase coincided with a period of increased purity and availability of MDMA in these markets, suggesting that changes in MDMA supply may result in serious public health risks. Furthermore, when factoring in the higher price of MDMA in Sweden, the market value in Stockholm is about 3.5 times that of Brussel